摘要
目的评价血脂康胶囊治疗血脂异常的临床效果和安全性。方法计算机检索PubMed、Web of Science核心集、中国知网、万方、维普等数据库中血脂康治疗血脂异常随机对照试验,检索时间截至2018年6月。采用Revman5.3软件进行Meta分析,系统评价血脂康对总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)的影响。结果共纳入25项随机对照试验、7875例患者。Meta分析显示:与空白对照组比较,血脂康明显降低TC(WMD=-1.05,95%CI:-1.40,-0.70,P<0.01)和LDL-C(WMD=-0.76,95%CI:-0.94,-0.58,P<0.01)水平,升高LDL-C水平(WMD=0.17,95%CI:0.08,0.27,P<0.01)。与他汀对照组比较,血脂康能升高HDL-C水平(WMD=0.17,95%CI:0.04,0.30,P<0.05),虽然也降低TC和LDL-C水平,但差异无统计学意义(P>0.05)。与对照组比较,血脂康不良反应/主要心脑血管事件发生率明显降低(WMD=0.55,95%CI:0.47,0.64,P<0.01)。结论血脂康能够有效、全面地调脂,并且不良事件发生率低。
Objective To evaluate the clinical efficacy and safety of Xuezhikang Capsules in the treatment of patients with dyslipidemia.Methods The databases of PubMed,Science Citation Index-Expanded,China National Knowledge Infrastructure,Wanfang Databases,Chinese VIP Information were searched up to June 2018 for randomized controlled trials about Xuezhikang in the treatment of dyslipidemia.Revman 5.3 software was used to make Meta-analysis.The effects of Xuezhikang Capsules on the serum levels of total cholesterol(TC),low density lipoprotein-cholesterol(LDL-C)and high density lipoprotein-cholesterol(HDL-C)were evaluated.Results A total of 25 trials containing 7875 participants were analyzed.Meta-analysis showed that compared with blank control group,Xuezhikang could lower serum levels of TC(WMD=-1.05,95%CI:-1.40,-0.70,P<0.01)and LDL-C(WMD=-0.76,95%CI:-0.94,-0.58,P<0.01)more effectively,and increase HDL-C(WMD=0.17,95%CI:0.08,0.27,P<0.01)more effectively.Compared with statins control group,Xuezhikang could increase HDL-C(WMD=0.17,95%CI:0.04,0.30,P<0.05)more effectively,and also decrease serum TC and LDL-C levels,while there were no significant differences(P>0.05).Compared with control group,Xuezhikang showed advantages in decreasing serious side effects or major adverse cardiovascular events(WMD=0.55,95%CI:0.47,0.64,P<0.01).Conclusion Xuezhikang can regulate dyslipidemia effectively and comprehensively,with low rates of adverse events.
作者
郑思道
杨翠
张成英
ZHENG Sidao;YANG Cui;ZHANG Chengying(Department of Cardiology,Beijing Hospital of Integrated Traditional Chinese and Western Medicine,Beijing 100039,China;Department of Cardiology,Huairou Hospital of Traditional Chinese Medicine,Beijing 101400,Chin)
出处
《中国医药导报》
CAS
2019年第14期51-55,78,共6页
China Medical Herald
基金
北京市优秀人才培养资助青年骨干个人项目(2014000057592G296)
